GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
Provided By GlobeNewswire
Last update: Mar 26, 2024
BRISBANE, CALIFORNIA, March 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced fourth quarter and full-year 2023 results for the period ended December 31, 2023.
Read more at globenewswire.comNASDAQ:GTBP (3/7/2025, 8:00:01 PM)
2.44
+0.07 (+2.95%)
Find more stocks in the Stock Screener
GTBP Latest News and Analysis
13 days ago - ChartmillTraders are paying attention to the gapping stocks in Tuesday's session.The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
13 days ago - ChartmillWhat's going on in today's pre-market sessionLet's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
